Advertisement
Advertisement
U.S. markets close in 5 hours 13 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Kala Pharmaceuticals, Inc. (KALA)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
16.93-0.41 (-2.36%)
As of 10:46AM EST. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close17.34
Open17.18
Bid16.88 x 3000
Ask17.00 x 1400
Day's Range16.81 - 17.35
52 Week Range3.54 - 97.00
Volume36,030
Avg. Volume2,560,786
Market Cap31.676M
Beta (5Y Monthly)-1.53
PE Ratio (TTM)N/A
EPS (TTM)-2.14
Earnings DateMar 27, 2023 - Mar 31, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est45.88
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for KALA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Kala Pharmaceuticals, Inc.
    Analyst Report: Regeneron Phars, IncRegeneron is a biopharmaceutical company focused on treatments for eye diseases, cancer, dermatitis, and rheumatoid arthritis. Founded in 1988, Regeneron has collaborated with Amgen, Procter & Gamble, Bayer, Sanofi, and Japan's Sumitomo Chemical. The company is a component of the S&P 500, has more than 10,900 employees worldwide, and is based in Tarrytown, New York.
    Rating
    Fair Value
    Economic Moat
    14 days agoArgus Research
View more
Advertisement
Advertisement